NurExone Biologic Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| J90.F | EXOZ | NCEL | XBIO | EXPRS2.ST | XCUR | |
|---|---|---|---|---|---|---|
| Market cap | 27.15M | 40.10M | 14.79M | 4.71M | 38.52M | 6.50M |
| P/E (TTM) | — | — | 4.9 | — | — | — |
| Forward P/E | — | — | -4.3 | -3.0 | 0.0 | -1.3 |
| Price/book | 25.5 | 10.9 | 2.3 | 0.8 | 0.6 | 6.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −18.32% | −68.07% | −43.83% | −26.10% | −93.98% | −75.37% |
| Today | −10.61% | −9.26% | −3.03% | −3.37% | −2.40% | −1.71% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All J90.F news ›Are NurExone Biologic (TSXV:NRX) Exosome Batch Developments Worth Watching?
Kalkine Media Western Energy Services (TSX:WRG) Revenue Rises, Fleet Shrinks Why Is Kinross Gold (TSX:K) Expanding Its Capital Return Plans? What Is Driving First Quantum Minerals’ (TSX:FM) Quarterly Recovery?
Why NurExone Biologic (TSXV:NRX) Is in Focus After Consistent Exosome Batch Data?
Consistency between batches is a known challenge in exosome therapeutics. Reproducible activity is important for regulators and manufacturing partners. Canadian healthcare and life sciences companies continue developing therapies, devices…
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone ” or the “... NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results TORONTO and HAIFA,…
NurExone Biologic Demonstrates Scalable Exosome Production With Two Bioreactors
NurExone Biologic (NRX.V,NRXBF) announced that it doubled exosome production by operating two bioreactors in parallel without increasing overall manufacturing time. The process maintained consistency and comparable exosome quality, marking…
NurExone Biologic Inc. announced that it has received CAD 1.066079 million in funding
NurExone Biologic Inc announced that it has completed non-brokered private placement of 1,938,326 units at the price of CAD 0.55 per share for the proceeds of CAD 1,066,078.02 on August 20, 2026. Each... Biotechnology & Medical Research…
NurExone Biologic Inc. Announces Board Changes
NurExone Biologic Inc. announced the appointment of Mr. David Stolick to its Board of Directors, effective July 28, 2026. Mr. Stolick succeeded the late James Jay Richardson, whose leadership helped... Published on 07/28/2026 at 05:24 pm…
NurExone Biologic Inc. Advances Optic Nerve Injury Program Toward Larger-Animal Study Following Positive Preclinical Results
NurExone Biologic Inc. announced new preclinical findings demonstrating the therapeutic benefits of its naïve exosomes and lead pharmaceutical drug candidate ExoPTEN in optic nerve injury models.... Biotechnology & Medical Research…
Nurexone Biologic Inc Demonstrates Scalable Exosome Production and Supports Modular Manufacturing Strategy
NurExone Biologic Inc. announced that it doubled exosome production by successfully operating two bioreactors in parallel, while maintaining the same overall production time, process consistency and... Biotechnology & Medical Research…
NurExone Biologic Inc. and Exolyra Llc Enter into Binding Memorandum of Understanding for Naïve Exosome Distribution in Mexico
NurExone Biologic Inc. announced that its wholly owned U.S. subsidiary, Exo-Top Inc., has entered into a binding memorandum of understanding setting out the principal commercial terms for a proposed... Biotechnology & Medical Research…
Nurexone Biologic Inc Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
NurExone Biologic Inc. announced new laboratory results demonstrating consistent anti-inflammatory activity across three batches of its naïve exosomes, supporting both its developing commercial supply ... Biotechnology & Medical Research…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com7
- kalkinemedia.com2
- markets.businessinsider.com1
- rttnews.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.